Finance entity
earnings is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ORIC Pharmaceuticals, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6.4 in the same window.
Last mentioned: Feb 23, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ORIC Pharmaceuticals, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6.4 in the same window. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. We currently track 1 Finance story that mention Tarsus Pharmaceuticals, all published on February 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 57 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Tarsus Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Tarsus Pharmaceuticals and ORIC Pharmaceuticals reported fourth-quarter 2025 results, highlighting a pivotal shift toward commercial scaling and clinical data maturation. While Tarsus focuses on the rapid adoption of XDEMVY, ORIC is advancing its oncology pipeline with key data readouts expected in 2026.
Tarsus Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
